MiNK Therapeutics to Participate at BTIG Biotechnology Conference
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference. The company will participate virtually and conduct one-on-one meetings with investors on August 8th and 9th. MiNK is advancing both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery. For more details, visit their website at minktherapeutics.com.
Details
News Market Reaction – INKT
The recorded move for INKT in the trading session of this news was -0.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will attend the BTIG 2022 Biotechnology Conference. MiNK will participate virtually and host one-on-one meetings with investors on August 8th and 9th.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.